December 6, 2016 / 12:22 PM / 8 months ago

BRIEF-Oncolytics provides initial data on combination therapy with Reolysin in multiple myeloma patients

1 Min Read

Dec 6 (Reuters) - Oncolytics Biotech Inc:

* Oncolytics Biotech Inc collaborators present initial results from REO 019 study in multiple myeloma combining Reolysin, bortezomib and dexamethasone at the ash annual meeting

* Oncolytics Biotech Inc - preliminary data suggest evidence of activity and that treatment combination was well tolerated Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below